Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Rhea-AI Summary

Cardiff Oncology, Inc. (Nasdaq: CRDF) will report its first quarter 2024 financial results on May 2, 2024, after the close of trading. The company will host a conference call and live webcast to discuss the results and provide a business update.

- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT -

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading.

Conference Call and Webcast

Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on May 2, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors.cardiffoncology.com/news-events/events. A replay will be available in the investor relations section on the company's website following the completion of the call.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com

Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com

Media Contact:
Grace Spencer
Taft Communications
609-583-1151
grace@taftcommunications.com 

FAQ

When will Cardiff Oncology report its first quarter 2024 financial results?

Cardiff Oncology will report its first quarter 2024 financial results on May 2, 2024, after the close of trading.

What is the ticker symbol for Cardiff Oncology?

The ticker symbol for Cardiff Oncology is CRDF.

What time will the conference call and webcast be held on May 2, 2024?

The conference call and webcast will be held at 4:30 p.m. ET/1:30 p.m. PT on May 2, 2024.

Where can individuals listen to the live conference call?

Individuals can listen to the live conference call by using the webcast link in the 'Investors' section of the company's website at https://investors.cardiffoncology.com/news-events/events.

Will a replay be available after the conference call?

Yes, a replay will be available in the investor relations section on the company's website following the completion of the call.